ABT-869 |
AL-39324 |
RG-3635 |
A-741439 |
LINIFANIB |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
Drug Class | Kinase Inhibitors |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Macrophage colony stimulating factor receptor inhibitor |
Trial Name | ABT-869, Linifanib |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Trial Name | ABT-869, Linifanib |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | ABT-869, Linifanib |
inhibitor (inhibitory) |
Trial Name | ABT-869, Linifanib |
Novel drug target | Established target |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Mechanism of Interaction | Vascular endothelial growth factor receptor inhibitor |
Direct Interaction | yes |
Trial Name | ABT-869, Linifanib |
inhibitor (inhibitory) |
Trial Name | ABT-869, Linifanib |
Novel drug target | Established target |
Notes |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase receptor FLT3 inhibitor |
Direct Interaction | yes |
Trial Name | ABT-869, Linifanib |
inhibitor (inhibitory) |
Trial Name | ABT-869, Linifanib |
Novel drug target | Established target |
inhibitor (inhibitory) |
Mechanism of Interaction | Platelet-derived growth factor receptor inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | ABT-869, Linifanib |
Novel drug target | Established target |
ABT-869 | Development Name |
LINIFANIB | Generic Name |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
LINIFANIB | Primary Drug Name |
LINIFANIB | Drug Generic Name |
ABT-869 | Drug Synonym |
CHEMBL223360 | ChEMBL Drug ID |
D0M9QZ | TTD Drug ID |